335318-29-1 Usage
Uses
Used in Pharmaceutical Industry:
4-Amino-2-benzylsulfanyl-pyrimidine-5-carbaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its potential antiviral, antifungal, and anticancer properties. Its benzylsulfanyl and aldehyde functional groups contribute to its reactivity and biological activity, making it a valuable building block in the development of new medicinal compounds.
Used in Agrochemical Industry:
4-Amino-2-benzylsulfanyl-pyrimidine-5-carbaldehyde is also used as an intermediate in the synthesis of agrochemicals. Its potential biological activities and functional groups make it a promising candidate for the development of new compounds with pesticidal or herbicidal properties, contributing to more effective and sustainable agricultural practices.
Check Digit Verification of cas no
The CAS Registry Mumber 335318-29-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,5,3,1 and 8 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 335318-29:
(8*3)+(7*3)+(6*5)+(5*3)+(4*1)+(3*8)+(2*2)+(1*9)=131
131 % 10 = 1
So 335318-29-1 is a valid CAS Registry Number.
335318-29-1Relevant academic research and scientific papers
6-Substituted pyrido-pyrimidines
-
, (2008/06/13)
The present invention provides compounds of the Formula I and II: wherein R1, R3, W, Z, X1, X2, Ar1, R8 and R9 are as defined herein, and methods and intermediates for their preparation and uses thereof.
Alkylamino-substituted bicyclic nitrogen heterocycles
-
Page/Page column 14, (2010/11/30)
Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives are provided which are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them.
Heteroalkylamino-substituted bicyclic nitrogen heterocycles
-
, (2008/06/13)
The invention provides compounds represented by the formula: wherein R1, R2, R3, R4, and n are as defined in the Summary of the Invention; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
